Detail Information of Exogenous Modulation

General Information of Drug Transporter (DT)
DT ID	DTD0503 Transporter Info
Gene Name	SLCO4C1
Transporter Name	Organic anion transporting polypeptide 4C1
Gene ID	353189
UniProt ID	Q6ZQN7

Exogenous factors (drugs, dietary constituents, etc.) Modulation of This DT (EGM)
Chemical Compound
DT Modulation1	Ritonavir inhibits the reaction SLCO4C1 protein affects the transport of traumatic acid		[47]
Regulation Mechanism			Transcription Factor Info
DT Modulation1	NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide results in increased expression of SLCO4C1 mRNA		[33]
Regulation Mechanism			Transcription Factor Info
DT Modulation1	NOG protein co-treated with Vorinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide results in increased expression of SLCO4C1 mRNA		[33]
Regulation Mechanism			Transcription Factor Info
DT Modulation1	NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide results in increased expression of SLCO4C1 mRNA		[33]
Regulation Mechanism			Transcription Factor Info
DT Modulation2	Valproic Acid affects the expression of SLCO4C1 mRNA		[52]
Regulation Mechanism			Transcription Factor Info
DT Modulation1	NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide results in increased expression of SLCO4C1 mRNA		[33]
Regulation Mechanism			Transcription Factor Info
DT Modulation1	Benzo(a)pyrene affects the methylation of SLCO4C1 3' UTR		[38]
Regulation Mechanism			Transcription Factor Info
DT Modulation2	Benzo(a)pyrene affects the methylation of SLCO4C1 promoter		[38]
Regulation Mechanism			Transcription Factor Info
DT Modulation3	Benzo(a)pyrene results in increased methylation of SLCO4C1 exon		[38]
Regulation Mechanism			Transcription Factor Info
1-Methyl-3-isobutylxanthine	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine results in increased expression of SLCO4C1 mRNA		[30]
Regulation Mechanism			Transcription Factor Info
1-Methyl-4-phenylpyridinium	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	1-Methyl-4-phenylpyridinium results in increased expression of SLCO4C1 mRNA		[20]
Regulation Mechanism			Transcription Factor Info
2-palmitoylglycerol	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	2-palmitoylglycerol results in increased expression of SLCO4C1 mRNA		[31]
Regulation Mechanism			Transcription Factor Info
3-iodothyronamine	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	SLCO4C1 mRNA affects the uptake of 3-iodothyronamine		[32]
Regulation Mechanism			Transcription Factor Info
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	9 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide results in increased expression of SLCO4C1 mRNA		[33]
Regulation Mechanism			Transcription Factor Info
DT Modulation2	NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide results in increased expression of SLCO4C1 mRNA		[33]
Regulation Mechanism			Transcription Factor Info
DT Modulation3	NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide results in increased expression of SLCO4C1 mRNA		[33]
Regulation Mechanism			Transcription Factor Info
DT Modulation4	NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide results in increased expression of SLCO4C1 mRNA		[33]
Regulation Mechanism			Transcription Factor Info
DT Modulation5	NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide results in increased expression of SLCO4C1 mRNA		[33]
Regulation Mechanism			Transcription Factor Info
DT Modulation6	NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide results in increased expression of SLCO4C1 mRNA		[33]
Regulation Mechanism			Transcription Factor Info
DT Modulation7	NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide results in increased expression of SLCO4C1 mRNA		[33]
Regulation Mechanism			Transcription Factor Info
DT Modulation8	NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide results in increased expression of SLCO4C1 mRNA		[33]
Regulation Mechanism			Transcription Factor Info
DT Modulation9	NOG protein co-treated with Vorinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide results in increased expression of SLCO4C1 mRNA		[33]
Regulation Mechanism			Transcription Factor Info
7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in decreased expression of SLCO4C1 mRNA		[34]
Regulation Mechanism			Transcription Factor Info
8-Bromo Cyclic Adenosine Monophosphate	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine results in increased expression of SLCO4C1 mRNA		[30]
Regulation Mechanism			Transcription Factor Info
aristolochic acid I	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	aristolochic acid I results in decreased expression of SLCO4C1 mRNA		[37]
Regulation Mechanism			Transcription Factor Info
belinostat	2 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	belinostat results in increased expression of SLCO4C1 mRNA		[11]
Regulation Mechanism			Transcription Factor Info
DT Modulation2	NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide results in increased expression of SLCO4C1 mRNA		[33]
Regulation Mechanism			Transcription Factor Info
butyraldehyde	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	butyraldehyde results in increased expression of SLCO4C1 mRNA		[21]
Regulation Mechanism			Transcription Factor Info
Cadmium Chloride	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Cadmium Chloride results in increased abundance of Cadmium which results in decreased expression of SLCO4C1 mRNA		[39]
Regulation Mechanism			Transcription Factor Info
Dexamethasone	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine results in increased expression of SLCO4C1 mRNA		[30]
Regulation Mechanism			Transcription Factor Info
dicrotophos	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	dicrotophos results in decreased expression of SLCO4C1 mRNA		[25]
Regulation Mechanism			Transcription Factor Info
di-n-butylphosphoric acid	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	di-n-butylphosphoric acid affects the expression of SLCO4C1 mRNA		[41]
Regulation Mechanism			Transcription Factor Info
dorsomorphin	9 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide results in increased expression of SLCO4C1 mRNA		[33]
Regulation Mechanism			Transcription Factor Info
DT Modulation2	NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide results in increased expression of SLCO4C1 mRNA		[33]
Regulation Mechanism			Transcription Factor Info
DT Modulation3	NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide results in increased expression of SLCO4C1 mRNA		[33]
Regulation Mechanism			Transcription Factor Info
DT Modulation4	NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide results in increased expression of SLCO4C1 mRNA		[33]
Regulation Mechanism			Transcription Factor Info
DT Modulation5	NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide results in increased expression of SLCO4C1 mRNA		[33]
Regulation Mechanism			Transcription Factor Info
DT Modulation6	NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide results in increased expression of SLCO4C1 mRNA		[33]
Regulation Mechanism			Transcription Factor Info
DT Modulation7	NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide results in increased expression of SLCO4C1 mRNA		[33]
Regulation Mechanism			Transcription Factor Info
DT Modulation8	NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide results in increased expression of SLCO4C1 mRNA		[33]
Regulation Mechanism			Transcription Factor Info
DT Modulation9	NOG protein co-treated with Vorinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide results in increased expression of SLCO4C1 mRNA		[33]
Regulation Mechanism			Transcription Factor Info
entinostat	2 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	entinostat results in increased expression of SLCO4C1 mRNA		[11]
Regulation Mechanism			Transcription Factor Info
DT Modulation2	NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide results in increased expression of SLCO4C1 mRNA		[33]
Regulation Mechanism			Transcription Factor Info
Homoarginine	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	SLCO4C1 protein results in increased export of Homoarginine		[42]
Regulation Mechanism			Transcription Factor Info
mercuric bromide	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide results in increased expression of SLCO4C1 mRNA		[33]
Regulation Mechanism			Transcription Factor Info
methylmercuric chloride	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	methylmercuric chloride results in decreased expression of SLCO4C1 mRNA		[43]
Regulation Mechanism			Transcription Factor Info
N,N-dimethylarginine	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	SLCO4C1 protein results in increased uptake of N,N-dimethylarginine		[42]
Regulation Mechanism			Transcription Factor Info
p-Chloromercuribenzoic Acid	2 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide results in increased expression of SLCO4C1 mRNA		[33]
Regulation Mechanism			Transcription Factor Info
DT Modulation2	p-Chloromercuribenzoic Acid results in increased expression of SLCO4C1 mRNA		[11]
Regulation Mechanism			Transcription Factor Info
perfluorooctane sulfonic acid	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	perfluorooctane sulfonic acid results in decreased expression of SLCO4C1 mRNA		[24]
Regulation Mechanism			Transcription Factor Info
potassium chromate(VI)	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	potassium chromate(VI) results in increased expression of SLCO4C1 mRNA		[19]
Regulation Mechanism			Transcription Factor Info
Raloxifene Hydrochloride	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Raloxifene Hydrochloride co-treated with ESR2 protein results in increased expression of SLCO4C1 mRNA		[46]
Regulation Mechanism			Transcription Factor Info
S-(1,2-dichlorovinyl)cysteine	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	S-(1,2-dichlorovinyl)cysteine affects the susceptibility to Lipopolysaccharides which results in increased expression of SLCO4C1 mRNA		[48]
Regulation Mechanism			Transcription Factor Info
Silicon Dioxide	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Silicon Dioxide analog results in increased expression of SLCO4C1 mRNA		[49]
Regulation Mechanism			Transcription Factor Info
sodium arsenite	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	sodium arsenite results in increased expression of SLCO4C1 mRNA		[19]
Regulation Mechanism			Transcription Factor Info
sulforaphane	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	sulforaphane results in increased expression of SLCO4C1 mRNA		[23]
Regulation Mechanism			Transcription Factor Info
Tamoxifen	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Tamoxifen co-treated with ESR2 protein results in increased expression of SLCO4C1 mRNA		[46]
Regulation Mechanism			Transcription Factor Info
Tetrachlorodibenzodioxin	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Tetrachlorodibenzodioxin results in decreased expression of SLCO4C1 mRNA		[35]
Regulation Mechanism			Transcription Factor Info
traumatic acid	2 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Ritonavir inhibits the reaction SLCO4C1 protein affects the transport of traumatic acid		[47]
Regulation Mechanism			Transcription Factor Info
DT Modulation2	SLCO4C1 protein affects the transport of traumatic acid		[47]
Regulation Mechanism			Transcription Factor Info
trichostatin A	2 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide results in increased expression of SLCO4C1 mRNA		[33]
Regulation Mechanism			Transcription Factor Info
DT Modulation2	trichostatin A results in increased expression of SLCO4C1 mRNA		[50]
Regulation Mechanism			Transcription Factor Info
triphenyl phosphate	2 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	triphenyl phosphate affects the expression of SLCO4C1 mRNA		[41]
Regulation Mechanism			Transcription Factor Info
DT Modulation2	triphenyl phosphate results in increased expression of SLCO4C1 mRNA		[51]
Regulation Mechanism			Transcription Factor Info
Nanoparticle
perfluoro-n-nonanoic acid	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	perfluoro-n-nonanoic acid results in decreased expression of SLCO4C1 mRNA		[45]
Regulation Mechanism			Transcription Factor Info
Approved Drug
Clarithromycin	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Clarithromycin inhibits the activity of SLCO4C1 (IC50 = 200 microM)		[1]
Crizotinib	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Crizotinib inhibits the activity of SLCO4C1 (IC50 = 24 microM)		[1]
Fluvastatin	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Fluvastatin inhibits the activity of SLCO4C1 (IC50 = 41 microM)		[1]
Levofloxacin	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Levofloxacin inhibits the activity of SLCO4C1 (IC50 = 420 microM)		[1]
Nicardipine	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Nicardipine inhibits the activity of SLCO4C1 (IC50 = 51 microM)		[1]
Ritonavir	2 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Ritonavir inhibits the activity of SLCO4C1 (IC50 = 8.5 microM)		[1]
Saquinavir	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Saquinavir inhibits the activity of SLCO4C1 (IC50 = 4.3 microM)		[1]
Spironolactone	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Spironolactone inhibits the activity of SLCO4C1 (IC50 = 53 microM)		[1]
Verapamil	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Verapamil inhibits the activity of SLCO4C1 (IC50 = 110 microM)		[1]
Amiodarone	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Amiodarone increases the expression of SLCO4C1		[2]
Atenolol	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Atenolol increases the expression of SLCO4C1		[3]
Isotretinoin	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Isotretinoin inhibits the expression of SLCO4C1		[4]
Estradiol	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Estradiol increases the expression of SLCO4C1		[5]
Azathioprine	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Azathioprine inhibits the expression of SLCO4C1		[6]
Vincristine	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Vincristine inhibits the expression of SLCO4C1		[7]
Zoledronic Acid	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Zoledronic Acid inhibits the expression of SLCO4C1		[8]
Methamphetamine	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Methamphetamine increases the expression of SLCO4C1		[9]
Doxorubicin	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Doxorubicin affects the expression of SLCO4C1		[10]
Belinostat	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Belinostat increases the expression of SLCO4C1		[11]
Panobinostat	2 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Panobinostat increases the expression of SLCO4C1		[11]
Vorinostat	2 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Vorinostat increases the expression of SLCO4C1		[11]
Rifampin	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Rifampin increases the expression of SLCO4C1		[12]
Sunitinib	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Sunitinib increases the expression of SLCO4C1		[13]
Cyclosporine	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Cyclosporine inhibits the expression of SLCO4C1		[14]
Tretinoin	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Tretinoin increases the expression of SLCO4C1		[15]
Valproic Acid	3 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Valproic Acid increases the expression of SLCO4C1		[16]
Digoxin	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Digoxin modulates the activity of SLCO4C1		[17]
Drug Marketed but not Approved by US FDA
Demecolcine	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Demecolcine inhibits the expression of SLCO4C1		[7]
Drug in Phase 3 Trial
Sulforafan	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Sulforafan increases the expression of SLCO4C1		[23]
Drug in Phase 2 Trial
MS-275	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	MS-275 increases the expression of SLCO4C1		[11]
Drug in Phase 1 Trial
Quercetin	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Quercetin inhibits the expression of SLCO4C1		[18]
Sodium arsenite	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Sodium arsenite increases the expression of SLCO4C1		[19]
Trichostatin A	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Trichostatin A increases the expression of SLCO4C1		[11]
Investigative Drug
Phenylmercuric Acetate	2 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Phenylmercuric Acetate increases the expression of SLCO4C1		[11]
Drug Withdrawn
Quinidine	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Quinidine inhibits the activity of SLCO4C1 (IC50 = 100 microM)		[1]
Natural Product
Tobacco Smoke Pollution	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Tobacco Smoke Pollution inhibits the expression of SLCO4C1		[29]
Caffeine	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Caffeine results in increased phosphorylation of SLCO4C1 protein		[40]
Regulation Mechanism			Transcription Factor Info
Environmental toxicant
Polychlorinated dibenzodioxin	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Polychlorinated dibenzodioxin inhibits the expression of SLCO4C1		[27]
Mycotoxins
Aflatoxin B1	3 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Aflatoxin B1 inhibits the expression of SLCO4C1		[28]
DT Modulation2	Aflatoxin B1 affects the expression of SLCO4C1 protein		[35]
Regulation Mechanism			Transcription Factor Info
DT Modulation3	Aflatoxin B1 results in increased methylation of SLCO4C1 intron		[36]
Regulation Mechanism			Transcription Factor Info
Acute Toxic Substance
Formaldehyde	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Formaldehyde inhibits the expression of SLCO4C1		[7]
Carcinogen
Ethyl Methanesulfonate	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Ethyl Methanesulfonate inhibits the expression of SLCO4C1		[7]
Benzo(a)pyrene	4 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Benzo(a)pyrene inhibits the expression of SLCO4C1		[26]
Cadmium	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Cadmium Chloride results in increased abundance of Cadmium which results in decreased expression of SLCO4C1 mRNA		[39]
Regulation Mechanism			Transcription Factor Info
Nickel	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Nickel results in decreased expression of SLCO4C1 mRNA		[44]
Regulation Mechanism			Transcription Factor Info
Pesticide/Insecticide
Dicrotophos	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Dicrotophos inhibits the expression of SLCO4C1		[25]
Health and Environmental Toxicant
1-methyl-4-phenylpyridinium	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	1-methyl-4-phenylpyridinium increases the expression of SLCO4C1		[20]
Butyraldehyde	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Butyraldehyde increases the expression of SLCO4C1		[21]
tris(1,3-dichloro-2-propyl)phosphate	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	tris(1,3-dichloro-2-propyl)phosphate affects the expression of SLCO4C1		[22]
Perfluorooctane sulfonic acid	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Perfluorooctane sulfonic acid inhibits the expression of SLCO4C1		[24]

References
1	Potential Drug Interactions Mediated by Renal Organic Anion Transporter OATP4C1. J Pharmacol Exp Ther. 2017 Aug;362(2):271-277.
2	Identification by automated screening of a small molecule that selectively eliminates neural stem cells derived from hESCs but not dopamine neurons. PLoS One. 2009 Sep 23;4(9):e7155.
3	Change in mRNA Expression after Atenolol, a Beta-adrenergic Receptor Antagonist and Association with Pharmacological Response. Arch Drug Inf. 2009 Sep;2(3):41-50.
4	Temporal changes in gene expression in the skin of patients treated with isotretinoin provide insight into its mechanism of action. Dermatoendocrinol. 2009 May;1(3):177-87.
5	Persistent and non-persistent changes in gene expression result from long-term estrogen exposure of MCF-7 breast cancer cells. J Steroid Biochem Mol Biol. 2011 Feb;123(3-5):140-50.
6	A transcriptomics-based in vitro assay for predicting chemical genotoxicity in vivo. Carcinogenesis. 2012 Jul;33(7):1421-9.
7	Characterization of formaldehyde's genotoxic mode of action by gene expression analysis in TK6 cells. Arch Toxicol. 2013 Nov;87(11):1999-2012.
8	Interleukin-19 as a translational indicator of renal injury. Arch Toxicol. 2015 Jan;89(1):101-6.
9	Methamphetamine alters the normal progression by inducing cell cycle arrest in astrocytes. PLoS One. 2014 Oct 7;9(10):e109603.
10	Identification of novel biomarkers for doxorubicin-induced toxicity in human cardiomyocytes derived from pluripotent stem cells. Toxicology. 2015 Feb 3;328:102-11.
11	A transcriptome-based classifier to identify developmental toxicants by stem cell testing: design, validation and optimization for histone deacetylase inhibitors. Arch Toxicol. 2015 Sep;89(9):1599-618.
12	Rifampin Regulation of Drug Transporters Gene Expression and the Association of MicroRNAs in Human Hepatocytes. Front Pharmacol. 2016 Apr 26;7:111.
13	Cell-based two-dimensional morphological assessment system to predict cancer drug-induced cardiotoxicity using human induced pluripotent stem cell-derived cardiomyocytes. Toxicol Appl Pharmacol. 2019 Nov 15;383:114761.
14	Integrating multiple omics to unravel mechanisms of Cyclosporin A induced hepatotoxicity in vitro. Toxicol In Vitro. 2015 Apr;29(3):489-501.
15	Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423.
16	Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
17	Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1227).
18	Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
19	Gene expression changes in human lung cells exposed to arsenic, chromium, nickel or vanadium indicate the first steps in cancer. Metallomics. 2012 Aug;4(8):784-93.
20	Transcriptional and metabolic adaptation of human neurons to the mitochondrial toxicant MPP(+). Cell Death Dis. 2014 May 8;5(5):e1222.
21	Integrated analysis of microRNA and mRNA expression profiles highlights aldehyde-induced inflammatory responses in cells relevant for lung toxicity. Toxicology. 2015 Aug 6;334:111-21.
22	Defensive and adverse energy-related molecular responses precede tris (1, 3-dichloro-2-propyl) phosphate cytotoxicity. J Appl Toxicol. 2016 May;36(5):649-58.
23	Sulforaphane-induced apoptosis in human leukemia HL-60 cells through extrinsic and intrinsic signal pathways and altering associated genes expression assayed by cDNA microarray. Environ Toxicol. 2017 Jan;32(1):311-328.
24	The role of hepatocyte nuclear factor 4-alpha in perfluorooctanoic acid- and perfluorooctanesulfonic acid-induced hepatocellular dysfunction. Toxicol Appl Pharmacol. 2016 Aug 1;304:18-29.
25	Molecular mechanisms of discrotophos-induced toxicity in HepG2 cells: The role of CSA in oxidative stress. Food Chem Toxicol. 2017 May;103:253-260.
26	Identification of a transcriptomic signature of food-relevant genotoxins in human HepaRG hepatocarcinoma cells. Food Chem Toxicol. 2020 Jun;140:111297.
27	The cutaneous lesions of dioxin exposure: lessons from the poisoning of Victor Yushchenko. Toxicol Sci. 2012 Jan;125(1):310-7.
28	Aflatoxin B1 induces persistent epigenomic effects in primary human hepatocytes associated with hepatocellular carcinoma. Toxicology. 2016 Mar 28;350-352:31-9.
29	Integration of transcriptome analysis with pathophysiological endpoints to evaluate cigarette smoke toxicity in an in vitro human airway tissue model. Arch Toxicol. 2021 May;95(5):1739-1761.
30	Role of endogenous TGF-beta in glucocorticoid-induced lung type II cell differentiation. Am J Physiol Lung Cell Mol Physiol. 2007;292(1):L249-57.
31	Direct effect of 2-palmitoyl glycerol on promotion of gamma aminobutyric acid synthesis in normal human fetal-derived astrocytes. FEBS Open Bio. 2023;13(7):1320-1332.
32	Identification and characterization of 3-iodothyronamine intracellular transport. Endocrinology. 2009 Apr;150(4):1991-9.
33	Definition of transcriptome-based indices for quantitative characterization of chemically disturbed stem cell development: introduction of the STOP-Toxukn and STOP-Toxukk tests. Arch Toxicol. 2017 Feb;91(2):839-864.
34	New insights into BaP-induced toxicity: role of major metabolites in transcriptomics and contribution to hepatocarcinogenesis. Arch Toxicol. 2016 Jun;90(6):1449-58.
35	Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
36	Effect of aflatoxin B(1), benzo[a]pyrene, and methapyrilene on transcriptomic and epigenetic alterations in human liver HepaRG cells. Food Chem Toxicol. 2018;121:214-223.
37	Integration of transcriptomic, proteomic and metabolomic data to reveal the biological mechanisms of AAI injury in renal epithelial cells. Toxicol In Vitro. 2021;70:105054.
38	Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017;8(1):1369-1391.
39	Cadmium acute exposure induces metabolic and transcriptomic perturbations in human mature adipocytes. Toxicology. 2022;470:153153.
40	Quantitative phosphoproteomics reveal cellular responses from caffeine, coumarin and quercetin in treated HepG2 cells. Toxicol Appl Pharmacol. 2022;449:116110.
41	Association between Organophosphate Ester Exposure and Insulin Resistance with Glycometabolic Disorders among Older Chinese Adults 60-69 Years of Age: Evidence from the China BAPE Study. Environ Health Perspect. 2023;131(4):47009.
42	The renal transport protein OATP4C1 mediates uptake of the uremic toxin asymmetric dimethylarginine (ADMA) and efflux of cardioprotective L-homoarginine. PLoS One. 2019;14(3):e0213747.
43	Stem Cell Transcriptome Responses and Corresponding Biomarkers That Indicate the Transition from Adaptive Responses to Cytotoxicity. Chem Res Toxicol. 2017 Apr 17;30(4):905-922.
44	Gene expression profiles in peripheral blood mononuclear cells of Chinese nickel refinery workers with high exposures to nickel and control subjects. Cancer Epidemiol Biomarkers Prev. 2013;22(2):261-9.
45	Perfluorooctanoic acid (PFOA), perfluorooctane sulfonic acid (PFOS), and perfluorononanoic acid (PFNA) increase triglyceride levels and decrease cholesterogenic gene expression in human HepaRG liver cells. Arch Toxicol. 2020 Sep;94(9):3137-3155.
46	Cell type- and estrogen receptor-subtype specific regulation of selective estrogen receptor modulator regulatory elements. Mol Cell Endocrinol. 2009;299(2):204-11.
47	Identification of a substrate of the renal tubular transporters for detecting drug-induced early acute kidney injury. Toxicol Sci. 2024;201(2):190-205.
48	The trichloroethylene metabolite S-(1,2-dichlorovinyl)-l-cysteine inhibits lipopolysaccharide-induced inflammation transcriptomic pathways and cytokine secretion in a macrophage cell model. Toxicol In Vitro. 2022;84:105429.
49	High-throughput, quantitative assessment of the effects of low-dose silica nanoparticles on lung cells: grasping complex toxicity with a great depth of field. BMC Genomics. 2015;16(1):315.
50	From transient transcriptome responses to disturbed neurodevelopment: role of histone acetylation and methylation as epigenetic switch between reversible and irreversible drug effects. Arch Toxicol. 2014 Jul;88(7):1451-68.
51	Adipogenic Effects and Gene Expression Profiling of Firemaster?550 Components in Human Primary Preadipocytes. Environ Health Perspect. 2017 Sep 14;125(9):097013.
52	Gene Expression Regulation and Pathway Analysis After Valproic Acid and Carbamazepine Exposure in a Human Embryonic Stem Cell-Based Neurodevelopmental Toxicity Assay. Toxicol Sci. 2015 Aug;146(2):311-20.

If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.

Detail Information of Exogenous Modulation

Visitor Map

Correspondence